Mechanisms of allergy and clinical immunologyEffects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge
Section snippets
Study subjects
Adult subjects between 18 and 50 years of age with a history of cat allergy were recruited by advertising from the greater Baltimore area. Informed consent was obtained via a protocol approved by the Johns Hopkins Hospital Institutional Review Board and the National Institute of Allergy and Infectious Diseases' Data Safety Monitoring Boards. Subjects met the following inclusion criteria for enrollment: a clinical history of cat-induced allergic rhinitis for at least 2 years with or without mild
Subject characteristics
Of the 18 enrolled subjects, 2 of the 14 subjects in the active treatment groups relocated before completion of all NACs. No significant differences were present between baseline characteristics in the 12 active and 4 placebo subjects who completed the study (Table I) or between the initial 14 enrolled subjects in the active group and the placebo group. Data for the 12 subjects on active treatment and the 4 subjects on placebo treatment who completed all 3 study NACs and procedures are reported
Discussion
In this study, we demonstrate a refined kinetics of serum and cellular changes by omalizumab. The expected ∼80% reduction in both basophil surface IgE and FcεRI expression in subjects 10 days after receiving omalizumab followed the expected decline in IgE (>90% in free IgE by day 3). Of note, significant, but modest reductions in cat allergen–induced BHR occurred as early as day 3 at the 0.1 BAU/mL dose (20% decline) and by day 18 at the 1 BAU/mL dose (35% decline) compared with greater
References (20)
Therapeutic efficacy of omalizumab
J Allergy Clin Immunol
(2009)- et al.
Omalizumab-induced reductions in mast cell Fce psilon RI expression and function
J Allergy Clin Immunol
(2004) - et al.
Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge
J Allergy Clin Immunol
(2005) - et al.
Objective monitoring of nasal patency and nasal physiology in rhinitis
J Allergy Clin Immunol
(2005) - et al.
Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions
J Allergy Clin Immunol
(1992) - et al.
Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils
J Allergy Clin Immunol
(2004) - et al.
Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis
Ann Allergy Asthma Immunol
(2004) - et al.
Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria
J Allergy Clin Immunol
(2007) - et al.
Expression and modulation of FcepsilonRIalpha and FcepsilonRIbeta in human blood basophils
J Allergy Clin Immunol
(2001) - et al.
Omalizumab for asthma
N Engl J Med
(2006)
Cited by (0)
S.S.S. and B.S.B. received support as Cosner Scholars in Translational Research from Johns Hopkins University. This work was supported by Asthma and Allergic Disease Research Centers grant U19AI070345 from the National Institutes of Health.
Disclosure of potential conflict of interest: S. S. Saini has served as a consultant for and has received research support from Genentech and Novartis. M. C. Liu has served as a consultant for the Novartis Advisory Board and has received research support from Pfizer, Centocor, and Novartis. D. W. MacGlashan Jr has received research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.